Plasma AR and abiraterone-resistant prostate cancer. - Wikidata - awgldk - TriplyDB

Plasma AR and abiraterone-resistant prostate cancer.

Plasma AR and abiraterone-resistant prostate cancer.

http://www.wikidata.org/entity/Q53810482

about

Galeterone for the treatment of advanced prostate cancer: the evidence to date Advances in genetics: widening our understanding of prostate cancer Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer Clonal origin and spread of metastatic prostate cancer Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer.Emerging concepts in liquid biopsies Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.Personalized prostate cancer care: from screening to treatment.Precision medicine for advanced prostate cancer.Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Detection fidelity of AR mutations in plasma derived cell-free DNA Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer.High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.Drug discovery in advanced prostate cancer: translating biology into therapy.Liquid biopsy: ready to guide therapy in advanced prostate cancer?A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer.The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.Liquid biopsies come of age: towards implementation of circulating tumour DNA.A population genetics perspective on the determinants of intra-tumor heterogeneity.Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors.

P2860

Q26739887-8A18FCE6-F236-494A-9576-E564C2DB29B0 Q26740628-B39FFD04-ECC1-421F-9488-9FF3864DA937 Q26751237-3EB16052-CE07-4351-8744-A02048949877 Q26752873-2AA1BED7-7AF4-4650-B2D0-ADC9CFD5FED1 Q28067556-912ACA91-3B55-454C-9DC1-449927C22944 Q30831010-488BE3D5-807D-4B13-82C7-2B0BE5C0EB9F Q36004694-FFF251AD-0034-41A3-AFC3-83B1C58C217D Q36337259-17A60A90-B3AC-46B7-B392-55E61FA924FE Q36398998-D661C02E-FFD1-43F2-9CD5-07EB2AC50214 Q36508759-9ADBCB0F-B41A-4F1B-998F-06DA19651405 Q37113160-3B5B659B-3981-4B60-8A91-8B8F3527D368 Q37114034-EC4D2003-5367-4DD7-B53B-0F1FFD9D1F8A Q37168845-DA9A61B9-140A-44E6-A11D-28F122BF2746 Q37349280-4BBF447D-0BBD-4E49-A7DA-57444B5F5531 Q37462283-DC2165A2-B9AD-47F6-B6A8-98E4EF20A2E4 Q37496652-FDE035F1-440E-48B0-93AC-F4F059398228 Q37709535-6A5E1B62-C59E-4A28-8140-3E4DE6D8032B Q37716596-0F595D96-C1DA-4484-A3A2-4E82827E6538 Q38375252-390CFBFF-5E7F-4C1B-B960-CD2C67E40640 Q38644658-2BB2B1FC-D3E6-488D-B350-2CDB20CC7789 Q38708804-8FCEF198-F974-4A1C-AD87-2BFBADF072B9 Q38718521-33A29821-7089-49E8-9DBA-742D8FB8FF9A Q38735379-12B78583-E389-4382-97CB-B481D1CDECFB Q38775459-19650C97-E608-4EF3-8F86-3804A45243F3 Q38797560-B3457C3C-5B8B-45AA-8D21-E51EA5B8F3D1 Q38804089-4F8FBEFD-DDAB-4EA5-A057-A78A019AB038 Q38815964-2568A2E0-07E9-4AB6-A152-82F7045EF554 Q38827364-A199E5B6-93FB-4BA5-9DD9-0C7FFB734825 Q38827723-6B57D165-FD9D-4FB1-94C4-174EF1B30F9A Q38835693-87E73311-DDD9-4964-8D6A-393EA5F50229 Q38839110-F658A3F3-C0A0-4E2A-9A7F-5DB75AF5F1BE Q38840458-4DB01981-AEA8-4E2D-BC51-F1EE0C8022DC Q38850529-F9E6DEC1-616F-4676-8FC6-520FE1EEAA1B Q38868832-3511DD75-A5A9-4C23-A0B7-B840D0B5C9E0 Q38982680-879E0F78-76E0-492A-BF63-3D3E0DDDEFB6 Q38994718-550CBF56-4C77-4383-B818-7DD4C4CB66DE Q39085996-CD8185B2-C4D1-45B0-9437-D194E0A2A637 Q39149201-F86EF61B-F6AC-431E-B1E1-7B8243D887AD Q39169154-06D4A7DA-1334-4F97-B35D-74FBFC84235C Q39186932-483474C2-0C7C-4B6F-83C0-4172B12F504C

P2860

Plasma AR and abiraterone-resistant prostate cancer.

http://www.wikidata.org/entity/Q53810482

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Plasma AR and abiraterone-resistant prostate cancer.

@en

Plasma AR and abiraterone-resistant prostate cancer.

@nl

type

label

Plasma AR and abiraterone-resistant prostate cancer.

@en

Plasma AR and abiraterone-resistant prostate cancer.

@nl

prefLabel

Plasma AR and abiraterone-resistant prostate cancer.

@en

Plasma AR and abiraterone-resistant prostate cancer.

@nl

P1433

Q53810482-F95A1A1C-5E2D-4913-8BAD-CC5FA074E4B8

P1476

Q53810482-5626BF57-FBBB-434A-9B95-E91B2874AD44

P2093

Q53810482-12E74FEA-186C-426B-9436-4EF0D3720A65

Q53810482-208F08D7-4139-43A4-BFCF-5486A0380897

Q53810482-4D0C57B8-04F0-40E9-9A50-2B15A12ADD6E

Q53810482-4FFB607B-313F-423B-974A-7642387E1D32

Q53810482-591C83DC-968B-4BCB-9E93-588C9E54504D

Q53810482-5DD64CBC-0271-4C24-A16B-C398B59DAFD9

Q53810482-720EC08A-D8A4-44EA-A40D-6C92DDD757C3

Q53810482-7C5CC43E-1F30-483D-879E-AD7E3191A2D0

Q53810482-853117D3-1310-4265-B7B2-2EC7A3E49ED0

Q53810482-B6AD2459-E60B-40CC-B3B5-69CE794F52F4

P2860

Q53810482-10251471-0CFD-4ACF-AB5F-A54AE134E203

Q53810482-115F0DD1-B839-44E0-B88E-9DF702B86D84

Q53810482-1A094415-8D05-4DEF-8C99-B0F4704817F7

Q53810482-1AF4FB14-201A-43F5-85D2-53B8B24409C7

Q53810482-29145338-272A-4010-9DA2-33533E661C9A

Q53810482-339D6CFB-0C74-4B48-B1BA-13FD4CD7AA5C

Q53810482-432F81D5-E258-4E16-A4AC-7A704687AE4B

Q53810482-444FF0EA-F2C6-4454-AF1B-168D3EF6BAC7

Q53810482-57AE9C34-9250-4981-A0BE-46841C5A4DCF

Q53810482-61FE5241-974B-4D45-B029-3A066A80105F

P304

Q53810482-3E2C4A74-0CE4-413C-9945-F48CE5F05875

P31

Q53810482-FDF150D9-5C54-4AEB-86C0-26632180370E

P356

Q53810482-E63BBF35-0A8D-4F84-B54B-3DBD1251D895

P407

Q53810482-6BFDF486-5666-4CEB-89B7-C9A37FD994F6

P433

Q53810482-5FA262F8-AA3D-4136-B88A-F411C061ED2A

P478

Q53810482-49931661-5C56-4517-82D4-D45146F4F739

P50

Q53810482-1EE11349-FF8F-47A7-9E75-28AF0709A33A

Q53810482-2CD745B1-104B-4283-A0E6-DDFC5AC1BA21

Q53810482-6FC05957-36A5-4170-A75D-5CEFB4F43D44

Q53810482-74BE6DF3-449E-44BC-AF14-C171D53954C8

Q53810482-7F0E5571-1919-4640-8C18-9D8A500A9941

Q53810482-86833C70-923B-4340-BCDA-167799E693FF

Q53810482-8B71039F-70AD-4D1B-A7B0-2D021D990B43

Q53810482-9F151AA9-268B-4E51-BED7-2983B272AE81

Q53810482-A2148EAC-1777-47A3-94DA-8F93C136CB84

Q53810482-FE820846-6D53-48D1-9DD8-A4414C3F8160

P577

Q53810482-6C47DB82-8DB6-4454-A747-B98FAF8CBDEE

P5875

Q53810482-06159A9E-821B-463F-9C1C-2EE74ACC3AE5

P698

Q53810482-B6EEAC27-34CC-42F1-8092-5F27794EC836

P932

Q53810482-D7E4160E-D31E-4CD8-B3F1-3CE2B7C49777

P356

SCITRANSLMED.AAC9511

P1433

Science Translational Medicine

P1476

Plasma AR and abiraterone-resistant prostate cancer

@en

P2093

Anna Wingate

http://www.w3.org/2001/XMLSchema#string

Anuradha Jayaram

http://www.w3.org/2001/XMLSchema#string

Daniel Wetterskog

http://www.w3.org/2001/XMLSchema#string

Diletta Bianchini

http://www.w3.org/2001/XMLSchema#string

Dino Amadori

http://www.w3.org/2001/XMLSchema#string

Jane Goodall

http://www.w3.org/2001/XMLSchema#string

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

Nicola Casiraghi

http://www.w3.org/2001/XMLSchema#string

Nina Tunariu

http://www.w3.org/2001/XMLSchema#string

Penny Flohr

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Integrative clinical genomics of advanced prostate cancer.

Molecular determinants of resistance to antiandrogen therapy

The Ka/Ks ratio: diagnosing the form of sequence evolution

Analysis of circulating tumor DNA to monitor metastatic breast cancer

Detection of circulating tumor DNA in early- and late-stage human malignancies

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

P304

312re10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.AAC9511

http://www.w3.org/2001/XMLSchema#string

P407

P433

312

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Gerhardt Attard

Francesca Demichelis

Pasquale Rescigno

Suzanne Carreira

Alessandro Romanel

Vincenza Conteduca

P577

2015-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283828673

http://www.w3.org/2001/XMLSchema#string

P698

26537258

http://www.w3.org/2001/XMLSchema#string

P932

6112410

http://www.w3.org/2001/XMLSchema#string